Program
progerinin
Its studies are led by PRG Science & Technology.
Furthest: phase 2, since Mar 31, 20233 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PRG Science & Technology | 31 open or running | phase 2since Mar 31, 2023 | Aug 6, 2020 | Dec 2027phase 2 · NCT05847179 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2020First study: phase 1 study in ProgeriaFirst studyNCT04512963 · 64 enrolled · United States
- Mar 31, 2023Phase 2 study in Werner SyndromeNCT05847179 · 5 planned · United States
- Dec 11, 2024Phase 2 study in ProgeriaNCT06775041 · 10 enrolled · United States
Ahead
- Dec 2027Primary completion: phase 2 study in Werner SyndromeNCT05847179
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06775041Progeria · United States | 2 | Completed | Mar 30, 2026 | 10 |
| NCT05847179Werner Syndrome · United States | 2 | Recruiting | Dec 2027 | 5 |
| NCT04512963Progeria · United States | 1 | Completed | Jul 27, 2021 | 64 |
How it is read
Names in the registry
- “Progerinin”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.